z-logo
open-access-imgOpen Access
The association of calcium channel blockers with β‐cell function in type 2 diabetic patients: A cross‐sectional study
Author(s) -
Zhao Dong,
Cao Yu,
Yu CaiGuo,
Yuan ShaSha,
Zhang Ning,
Zhang YuanYuan,
Staessen Jan A.,
Feng YingMei
Publication year - 2019
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/jch.13517
Subject(s) - medicine , diabetes mellitus , type 2 diabetes mellitus , c peptide , calcium channel , endocrinology , antihypertensive drug , type 2 diabetes , cross sectional study , calcium , blood pressure , pathology
Type 2 diabetes mellitus (T2DM) patients are often accompanied with hypertension. However, the association of antihypertensive drugs with β‐cell function has not been well studied. To investigate this question, the authors performed a cross‐sectional study involving 882 hypertensive T2DM patients. To assess β‐cell function, patients were given 75g glucose orally and C‐peptide levels before and 1, 2, and 3 hours after glucose intake were measured. Homa‐β was computed by Homeostasis Model Assessment model to evaluate β‐cell function using fasting C‐peptide and glucose levels in the plasma. Multivariable‐adjusted analysis was performed to evaluate the association of antihypertensive drugs with C‐peptide levels, HbA1c, and Homa‐β. Among 882 hypertensive patients, 547 (62.0%) received antihypertensive treatment. Multivariate‐adjusted analysis demonstrated that use of calcium channel blockers (CCBs) was negatively associated with HbA1c levels (CCBs: 0.95 [95% CI: 0.92‐0.98], P  = 0.002). Our data further illustrated that the C‐peptide levels before and 1, 2, and 3 hours of OGTT were 1.10‐, 1.18‐, 1.19‐, and 1.15‐fold increase in T2DM patients taking CCBs ( P  = 0.084 for fasting C‐peptide levels; P  ≤ 0.024 for C‐peptide levels at 1, 2, and 3 hours after OGTT) in comparison with non‐CCB users. Nevertheless, usage of any other antihypertensive drugs did neither associated with HbA1c nor associated with C‐peptide levels ( P  ≥ 0.11). In conclusion, CCB treatment was negatively associated with HbA1c levels but positively associated with β‐cell function in hypertensive T2DM patients, implying that CCBs could be considered to treat hypertensive T2DM patients with reduced β‐cell function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here